CAJ | 학술논문

目的：观察TACE联合卡培他滨对原发性肝癌患者生存的影响。方法原发性肝癌患者57例，分为TACE联合卡培他滨组和TACE组：TACE联合组28例，采用肝动脉化疗栓塞联合卡培他滨治疗；TACE组29例，单纯采用肝动脉化疗栓塞治疗。观察两组患者的疗效及患者的生存时间。结果 TACE联合组RR为32.1%，TACE组RR为10.3%，两组RR的差异有统计学意义(P＜0.05)。TACE组的中位生存期为10.0个月，1年生存率37.9%，TACE联合组的中位生存期为16.3个月，1年生存率60.7%，均优于TACE组，差异有统计学意义(P＜0.05)。结论 TACE联合卡培他滨可显著提高肝癌患者的疗效，延长生存时间。
목적：관찰TACE연합잡배타빈대원발성간암환자생존적영향。방법원발성간암환자57례，분위TACE연합잡배타빈조화TACE조：TACE연합조28례，채용간동맥화료전새연합잡배타빈치료；TACE조29례，단순채용간동맥화료전새치료。관찰량조환자적료효급환자적생존시간。결과 TACE연합조RR위32.1%，TACE조RR위10.3%，량조RR적차이유통계학의의(P＜0.05)。TACE조적중위생존기위10.0개월，1년생존솔37.9%，TACE연합조적중위생존기위16.3개월，1년생존솔60.7%，균우우TACE조，차이유통계학의의(P＜0.05)。결론 TACE연합잡배타빈가현저제고간암환자적료효，연장생존시간。
Objective To observe the effects of TACE combined with capecitabine on the survival of primary hepatic carcinoma patients. Methods The 57 primary hepatic carcinoma patients were collected. The patients were divided into observation and control groups. The 28 patients in the observation group received TACE combined with capecitabine. The 29 patients in the control group received TACE only. The curative effects, survival time, 1 year survival rates were observed. Results The total RR of the observation group was 32.1%, which was signiifcantly higher than that of the control group (10.3%). Moreover, the 1 year survival rate of the observation group was 60.7%, which was signiifcantly higher than that of the control group (37.9%). The signiifcant differences in RR and OS were observed between the two groups (P<0.05). Conclusion TACE combined with capecitabine could improve the curative effect, prolong the survival time of primary hepatic carcinoma patients.